{"title":"Cardiovascular Risks of Electronic Cigarettes: Mechanisms, Evidence, and Research Gaps.","authors":"Pandey Pratima, Anit Kumar Sinha, Basant Kumar","doi":"10.2174/0115701611416438251216071232","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Electronic cigarettes (ECs), or electronic nicotine delivery systems (ENDS), are increasingly promoted as safer alternatives to conventional cigarettes, especially among younger populations. However, concerns remain regarding their cardiovascular effects.</p><p><strong>Methods: </strong>This review synthesized evidence from PubMed, Embase, and Web of Science databases to examine the association between e-cigarette use and cardiovascular health. Eligible sources included observational studies, experimental research, and systematic reviews evaluating exposure to nicotine and other harmful compounds present in e-cigarettes.</p><p><strong>Results: </strong>Evidence indicates that e-cigarette use exposes individuals to harmful chemicals such as nicotine and carbonyl compounds, which are linked to endothelial dysfunction, arrhythmias, coronary artery disease, and progression of atherosclerosis. While some studies suggest reduced exposure to ecigarettes compared with conventional smoking, measurable adverse cardiovascular outcomes remain significant.</p><p><strong>Discussion: </strong>The findings suggest that although e-cigarettes may serve a role in harm reduction and smoking cessation, their potential to induce cardiovascular risk cannot be overlooked. Current evidence highlights both short-term vascular changes and possible long-term health consequences, though robust longitudinal data remain limited.</p><p><strong>Conclusion: </strong>E-cigarette use is associated with cardiovascular risks despite being marketed as a safer alternative to traditional smoking. There is an urgent need for comprehensive, long-term studies and public health initiatives to clarify these risks and guide appropriate regulatory policies.</p>","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current vascular pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115701611416438251216071232","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Electronic cigarettes (ECs), or electronic nicotine delivery systems (ENDS), are increasingly promoted as safer alternatives to conventional cigarettes, especially among younger populations. However, concerns remain regarding their cardiovascular effects.
Methods: This review synthesized evidence from PubMed, Embase, and Web of Science databases to examine the association between e-cigarette use and cardiovascular health. Eligible sources included observational studies, experimental research, and systematic reviews evaluating exposure to nicotine and other harmful compounds present in e-cigarettes.
Results: Evidence indicates that e-cigarette use exposes individuals to harmful chemicals such as nicotine and carbonyl compounds, which are linked to endothelial dysfunction, arrhythmias, coronary artery disease, and progression of atherosclerosis. While some studies suggest reduced exposure to ecigarettes compared with conventional smoking, measurable adverse cardiovascular outcomes remain significant.
Discussion: The findings suggest that although e-cigarettes may serve a role in harm reduction and smoking cessation, their potential to induce cardiovascular risk cannot be overlooked. Current evidence highlights both short-term vascular changes and possible long-term health consequences, though robust longitudinal data remain limited.
Conclusion: E-cigarette use is associated with cardiovascular risks despite being marketed as a safer alternative to traditional smoking. There is an urgent need for comprehensive, long-term studies and public health initiatives to clarify these risks and guide appropriate regulatory policies.
电子烟(ECs)或电子尼古丁传递系统(ENDS)作为传统香烟的更安全替代品日益得到推广,特别是在年轻人群中。然而,人们仍然担心它们对心血管的影响。方法:本综述综合了来自PubMed、Embase和Web of Science数据库的证据,以检验电子烟使用与心血管健康之间的关系。合格的来源包括观察性研究、实验研究和评估电子烟中尼古丁和其他有害化合物暴露的系统综述。结果:有证据表明,电子烟的使用使个人暴露于尼古丁和羰基化合物等有害化学物质中,这些化学物质与内皮功能障碍、心律失常、冠状动脉疾病和动脉粥样硬化的进展有关。虽然一些研究表明,与传统吸烟相比,电子烟的暴露减少了,但可测量的心血管不良后果仍然很明显。讨论:研究结果表明,尽管电子烟可能在减少危害和戒烟方面发挥作用,但它们诱发心血管风险的潜力不容忽视。目前的证据强调了短期血管变化和可能的长期健康后果,尽管可靠的纵向数据仍然有限。结论:尽管电子烟被宣传为比传统吸烟更安全的替代品,但电子烟的使用与心血管风险有关。迫切需要进行全面的长期研究和公共卫生倡议,以澄清这些风险并指导适当的监管政策。
期刊介绍:
Current Vascular Pharmacology publishes clinical and research-based reviews/mini-reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research.
Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).